Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Characterization of Blimp-1 function in effector regulatory T cells.

Cretney E, Leung PS, Trezise S, Newman DM, Rankin LC, Teh CE, Putoczki TL, Gray DH, Belz GT, Mielke LA, Dias S, Nutt SL.

J Autoimmun. 2018 Jul;91:73-82. doi: 10.1016/j.jaut.2018.04.003. Epub 2018 Apr 30.

PMID:
29724515
2.

Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model.

Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, Weston RA, Scheller KJ, Djouma E, Menon P, Schibeci SD, Marmash N, Yerbury JJ, Nutt SL, Booth DR, Stewart GJ, Kiernan MC, Vucic S, Turner BJ.

JAMA Neurol. 2018 Jun 1;75(6):681-689. doi: 10.1001/jamaneurol.2018.0035.

3.

Inclusion of BLIMP-1+ effector regulatory T cells improves the Immunoscore in a cohort of New Zealand colorectal cancer patients: a pilot study.

Ward-Hartstonge KA, McCall JL, McCulloch TR, Kamps AK, Girardin A, Cretney E, Munro FM, Kemp RA.

Cancer Immunol Immunother. 2017 Apr;66(4):515-522. doi: 10.1007/s00262-016-1951-1. Epub 2017 Jan 23.

PMID:
28116480
4.

Effector Regulatory T Cell Differentiation and Immune Homeostasis Depend on the Transcription Factor Myb.

Dias S, D'Amico A, Cretney E, Liao Y, Tellier J, Bruggeman C, Almeida FF, Leahy J, Belz GT, Smyth GK, Shi W, Nutt SL.

Immunity. 2017 Jan 17;46(1):78-91. doi: 10.1016/j.immuni.2016.12.017.

5.

Th17 cell differentiation proceeds independently of IRF8.

Newman DM, Leung PS, Putoczki TL, Nutt SL, Cretney E.

Immunol Cell Biol. 2016 Sep;94(8):796-801. doi: 10.1038/icb.2016.33. Epub 2016 May 3.

PMID:
27140932
6.

Correction: Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology.

Montes de Oca M, Kumar R, de Labastida Rivera F, Amante FH, Sheel M, Faleiro RJ, Bunn PT, Best SE, Beattie L, Ng SS, Edwards CL, Muller W, Cretney E, Nutt SL, Smyth MJ, Haque A, Hill GR, Sundar S, Kallies A, Engwerda CR.

PLoS Pathog. 2016 Feb 12;12(2):e1005460. doi: 10.1371/journal.ppat.1005460. eCollection 2016 Feb. No abstract available.

7.

Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology.

Montes de Oca M, Kumar R, de Labastida Rivera F, Amante FH, Sheel M, Faleiro RJ, Bunn PT, Best SE, Beattie L, Ng SS, Edwards CL, Muller W, Cretney E, Nutt SL, Smyth MJ, Haque A, Hill GR, Sundar S, Kallies A, Engwerda CR.

PLoS Pathog. 2016 Jan 14;12(1):e1005398. doi: 10.1371/journal.ppat.1005398. eCollection 2016 Jan. Erratum in: PLoS Pathog. 2016 Feb;12(2):e1005460.

8.

Maternal Diet during Pregnancy Induces Gene Expression and DNA Methylation Changes in Fetal Tissues in Sheep.

Lan X, Cretney EC, Kropp J, Khateeb K, Berg MA, Peñagaricano F, Magness R, Radunz AE, Khatib H.

Front Genet. 2013 Apr 5;4:49. doi: 10.3389/fgene.2013.00049. eCollection 2013.

9.

Keeping memories alive.

Belz GT, Cretney E.

Front Immunol. 2013 Feb 1;4:21. doi: 10.3389/fimmu.2013.00021. eCollection 2013. No abstract available.

10.

Differentiation and function of Foxp3(+) effector regulatory T cells.

Cretney E, Kallies A, Nutt SL.

Trends Immunol. 2013 Feb;34(2):74-80. doi: 10.1016/j.it.2012.11.002. Epub 2012 Dec 6. Review.

PMID:
23219401
11.

The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells.

Cretney E, Xin A, Shi W, Minnich M, Masson F, Miasari M, Belz GT, Smyth GK, Busslinger M, Nutt SL, Kallies A.

Nat Immunol. 2011 Apr;12(4):304-11. doi: 10.1038/ni.2006. Epub 2011 Mar 6.

PMID:
21378976
12.

Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim.

Kaufmann T, Jost PJ, Pellegrini M, Puthalakath H, Gugasyan R, Gerondakis S, Cretney E, Smyth MJ, Silke J, Hakem R, Bouillet P, Mak TW, Dixit VM, Strasser A.

Immunity. 2009 Jan 16;30(1):56-66. doi: 10.1016/j.immuni.2008.10.017.

13.

Age-dependent, polyclonal hyperactivation of T cells is reduced in TNF-negative gld/gld mice.

Wiede F, Roomberg A, Cretney E, Lechner A, Fromm P, Wren L, Smyth MJ, Körner H.

J Leukoc Biol. 2009 Jan;85(1):108-16. doi: 10.1189/jlb.0107018. Epub 2008 Oct 23.

PMID:
18948547
14.

Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.

Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, Okumura K, Aoyama T, Frese S, Ikeda H, Haynes NM, Cretney E, Yagita H, Sueyoshi N, Sato N, Nakanuma Y, Smyth MJ, Okumura K.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10895-900. doi: 10.1073/pnas.0802702105. Epub 2008 Jul 30.

15.

No requirement for TRAIL in intrathymic negative selection.

Cretney E, Uldrich AP, McNab FW, Godfrey DI, Smyth MJ.

Int Immunol. 2008 Feb;20(2):267-76. doi: 10.1093/intimm/dxm144. Epub 2008 Jan 11.

PMID:
18192669
16.

Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.

Cretney E, Takeda K, Smyth MJ.

Int J Biochem Cell Biol. 2007;39(2):280-6. Epub 2006 Oct 7. Review.

PMID:
17097329
17.

NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function.

Abdool K, Cretney E, Brooks AD, Kelly JM, Swann J, Shanker A, Bere EW Jr, Yokoyama WM, Ortaldo JR, Smyth MJ, Sayers TJ.

J Immunol. 2006 Aug 15;177(4):2575-83.

18.

IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy.

Smyth MJ, Hayakawa Y, Cretney E, Zerafa N, Sivakumar P, Yagita H, Takeda K.

J Immunol. 2006 May 15;176(10):6347-55.

19.

TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.

Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ.

Immunol Cell Biol. 2006 Feb;84(1):87-98. Review. Erratum in: Immunol Cell Biol. 2006 Apr;84(2):238.

PMID:
16405656
20.

Cutting edge: TRAIL deficiency accelerates hematological malignancies.

Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, Smyth MJ.

J Immunol. 2005 Nov 1;175(9):5586-90.

21.

TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice.

Cretney E, McQualter JL, Kayagaki N, Yagita H, Bernard CC, Grewal IS, Ashkenazi A, Smyth MJ.

Immunol Cell Biol. 2005 Oct;83(5):511-9.

PMID:
16174101
22.

NKG2D function protects the host from tumor initiation.

Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y.

J Exp Med. 2005 Sep 5;202(5):583-8. Epub 2005 Aug 29.

23.

Functional analysis of granzyme M and its role in immunity to infection.

Pao LI, Sumaria N, Kelly JM, van Dommelen S, Cretney E, Wallace ME, Anthony DA, Uldrich AP, Godfrey DI, Papadimitriou JM, Mullbacher A, Degli-Esposti MA, Smyth MJ.

J Immunol. 2005 Sep 1;175(5):3235-43.

24.

Are we really on the right TRAIL?

Cretney E, Uldrich AP, Berzins SP, Strasser A, Godfrey DI, Smyth MJ.

Immunol Res. 2005;31(2):161-4. Review. No abstract available.

PMID:
15778513
25.

Activation of NK cell cytotoxicity.

Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, Takeda K, van Dommelen SL, Degli-Esposti MA, Hayakawa Y.

Mol Immunol. 2005 Feb;42(4):501-10. Review.

PMID:
15607806
26.

Cytokines in cancer immunity and immunotherapy.

Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y.

Immunol Rev. 2004 Dec;202:275-93. Review.

PMID:
15546400
27.

NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.

Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, Sayers TJ, Hayakawa Y.

J Exp Med. 2004 Nov 15;200(10):1325-35.

28.

TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver.

Takeda K, Cretney E, Hayakawa Y, Ota T, Akiba H, Ogasawara K, Yagita H, Kinoshita K, Okumura K, Smyth MJ.

Blood. 2005 Mar 1;105(5):2082-9. Epub 2004 Nov 9.

PMID:
15536146
29.

Re: Immunologic Research review (Zheng S-J and Chen YH. TRAIL, Bim, and Thymic-Negative Selection. Immunol. Res. 2003; 28/3:295-301).

Smyth MJ, Cretney E.

Immunol Res. 2004;30(2):255-6; author reply 257-9. No abstract available.

PMID:
15477665
30.

The functional basis for hemophagocytic lymphohistiocytosis in a patient with co-inherited missense mutations in the perforin (PFN1) gene.

Voskoboinik I, Thia MC, De Bono A, Browne K, Cretney E, Jackson JT, Darcy PK, Jane SM, Smyth MJ, Trapani JA.

J Exp Med. 2004 Sep 20;200(6):811-6. Epub 2004 Sep 14.

31.

Granzyme M mediates a novel form of perforin-dependent cell death.

Kelly JM, Waterhouse NJ, Cretney E, Browne KA, Ellis S, Trapani JA, Smyth MJ.

J Biol Chem. 2004 May 21;279(21):22236-42. Epub 2004 Mar 17.

32.

Normal thymocyte negative selection in TRAIL-deficient mice.

Cretney E, Uldrich AP, Berzins SP, Strasser A, Godfrey DI, Smyth MJ.

J Exp Med. 2003 Aug 4;198(3):491-6.

33.

TNF contributes to the immunopathology of perforin/Fas ligand double deficiency.

Cretney E, Street SE, Smyth MJ.

Immunol Cell Biol. 2002 Oct;80(5):436-40.

PMID:
12225379
34.

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.

Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H, Okumura K.

Cell Immunol. 2001 Dec 15;214(2):194-200.

PMID:
12088418
35.

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development.

Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura K.

J Exp Med. 2002 Jan 21;195(2):161-9.

36.

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.

Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ.

J Immunol. 2002 Feb 1;168(3):1356-61.

37.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.

Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K.

J Exp Med. 2001 Mar 19;193(6):661-70.

38.
39.

Cytomegalovirus MHC class I homologues and natural killer cells: an overview.

Farrell H, Degli-Esposti M, Densley E, Cretney E, Smyth M, Davis-Poynter N.

Microbes Infect. 2000 Apr;2(5):521-32. Review.

PMID:
10865197
40.

Differential tumor surveillance by natural killer (NK) and NKT cells.

Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI.

J Exp Med. 2000 Feb 21;191(4):661-8.

41.

Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype.

Körner H, Cretney E, Wilhelm P, Kelly JM, Röllinghoff M, Sedgwick JD, Smyth MJ.

J Exp Med. 2000 Jan 3;191(1):89-96. Erratum in: J Exp Med 2000 Apr 17;191(8):following 1948.

42.

m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection.

Cretney E, Degli-Esposti MA, Densley EH, Farrell HE, Davis-Poynter NJ, Smyth MJ.

J Exp Med. 1999 Aug 2;190(3):435-44.

43.

Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice.

Smyth MJ, Johnstone RW, Cretney E, Haynes NM, Sedgwick JD, Korner H, Poulton LD, Baxter AG.

J Immunol. 1999 Aug 1;163(3):1350-3.

44.

Perforin is a major contributor to NK cell control of tumor metastasis.

Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA.

J Immunol. 1999 Jun 1;162(11):6658-62.

45.

Supplemental Content

Loading ...
Support Center